GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

Graft Vs Host Disease Clinical Trial

Official title:

GVHD Prophylaxis With Methotrexate and Cyclosporine in Haploidentical Stem Cell Transplantation Using Posttransplant Cyclophosphamide in Hematologic Malignancies: Phase I/II Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04622956
• Other study ID #: 30802020.7.1001.0068
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 7, 2020
• Est. completion date: December 2025

Study information

• Verified date: September 2021
• Source: University of Sao Paulo General Hospital
• Contact: Giancarlo Fatobene, MD
• Phone: +551126617575
• Email: gian_fatobene[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic strategy for many malignant and benign hematologic diseases. Haploidentical HCT has been increasingly used in patients lacking a HLA-matched donor due to its prompt availability, possibly lower cost and results comparable with other donor types. Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality after HSCT, and prophylactic strategies are routinely used. In the context of haploidentical HCT, posttransplant cyclophosphamide plus cyclosporine and mycophenolate mofetil (MMF) is the most common platform used in Brazil. Data comparing MMF and methotrexate (MTX) as GVHD prophylaxes have proved controversial in other donor types, yet some large studies have showed that MTX is associated with lower risk of GVHD and improved long-term outcomes. Moreover, it is known that MMF is a potent inhibitor of natural killer (NK) cells, possibly interfering with the graft-versus-leukemia effect in haploidentical HCT. Given the possible advantages and the absence of consistent evidence regarding safety, efficacy and ideal dosage of MTX as GVHD prophylaxis in this setting, we propose a phase I / II study evaluating this drug in adult patients with hematologic malignancies undergoing haploidentical HCT with posttransplant cyclophosphamide.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 47
• Est. completion date: December 2025
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosis of acute myeloid leukemia and chronic myeloid leukemia in complete morphologic remission, myelodysplastic syndrome with less than 10% in bone marrow or peripheral blood, Ph-negative acute lymphoblastic leukemia in complete morphologic remission, chemosensitive Hodgkin lymphoma or non-Hodgkin lymphoma in at least partial remission
• Donor type: haploidentical related donor
• Graft source: bone marrow or peripheral blood
• Recipients of non-myeloblative or myeloablative intensity conditioning
• Left Ventricle Ejection fraction > 40%
• Estimated creatinine clearance > 40 mL/min
• Adjusted DLCO = 40% and FEV1 = 40%
• Total bilirubin < 2x ULN e ALT/AST < 2.5x ULN

Exclusion Criteria:

• Prior allogeneic transplant
• Ex-vivo graft manipulation (T-cell-depleted or CD34-selected grafts)
• Use of alemtuzumab or anti-thymocyte globulin
• KPS < 70%
• Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment
• Pregnant or lactating women
• Patients seropositive for human immunodeficiency virus (HIV) or active hepatitis B or C infection by PCR
• Presence of fluid collection (ascites, pleural or pericardial effusion) that may interfere with methotrexate clearance or make methotrexate use contraindicated
• Patients with a serious medical or psychiatric illness likely to interfere with participation in this study

Related Conditions & MeSH terms

• Graft Vs Host Disease
• Hematologic Neoplasms
• Hematopoietic Neoplasm

Intervention

Drug:
• Methotrexate Injectable Solution
Phase 1: Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9*. Level -1 will be explored only if the starting dose is too toxic (reduced dose). Level 0 [Starting Dose]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9 Level +1: Methotrexate 10 mg/m2 on D+6 and D+9 Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9 Phase 2: dose determined in the phase 1 trial

Locations

Country	Name	City	State
Brazil	Centro de Hematologia e Hemoterapia - HEMOCENTRO	Campinas	São Paulo
Brazil	Hospital Amaral Carvalho / Fundação Dr. Amaral Carvalho	Jaú	São Paulo
Brazil	Instituto Nacional de Câncer José Alencar Gomes Da Silva - Inca	Rio De Janeiro	RJ
Brazil	Hospital das Clinicas da Universidade de Sao Paulo	Sao Paulo

Sponsors (2)

Lead Sponsor	Collaborator
University of Sao Paulo General Hospital	Libbs Farmacêutica LTDA

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Methotrexate dose to be used in the phase 2 (Phase 1)	The methotrexate dose to be used in the subsequent phase 2 will be equal to or lower than the maximum tolerated dose (MTD). MTD will be considered exceeded if at least 2 out of 6 subjects on a certain dosing level develop dose-limiting toxicity (DLT). DLT consists of gastrointestinal tract perforation, mediastinitis, airway obstruction requiring orotracheal intubation, severe gastrointestinal bleeding (without evidence of GVHD), graft failure, or hyperbilirubinemia or increase in alanine transaminase [ALT] / aspartate transaminase [AST] levels > 5x the upper limit of normal.	Day 30
Primary	GVHD-free, relapse-free survival (Phase 2)	Relapse, grade 3-4 GVHD and 2014 NIH Chronic GVHD will be considered events, and non-relapse related mortality will be a competing event.	Day 365
Secondary	Overall survival	Time to death	Day 365
Secondary	Cumulative incidence of neutrophil and platelet engraftment	Neutrophil engraftment will be the first of three consecutive daily absolute neutrophil counts > 500 / mcL after transplantation. Disease relapse will be a competitive event. Platelet engraftment will be considered as the first of seven daily consecutive platelet counts > 20,000 / mcL without transfusion support. Disease relapse will be a competitive event.	Day 30
Secondary	Cumulative incidence of graft failure	Time to primary or secondary graft failure. Primary graft failure will be defined as failure to reach neutrophils > 500 / mcL for three consecutive days or donor chimerism <5% in any hematopoietic compartment (lymphocyte chimerism or total bone marrow / peripheral blood chimerism) and requiring additional hematopoietic cells. Secondary graft failure will be defined as the need for additional hematopoietic cells due to declining hematopoietic recovery in a patient with previous neutrophil engraftment.	Day 30
Secondary	Cumulative incidence of grade II-IV acute GVHD	Time to onset of grade II-IV acute GVHD according to the MAGIC criteria. Death without previous acute GVHD will be a competing event.	Day 100
Secondary	Cumulative incidence of grade III-IV acute GVHD	Time to onset of grade III-IV acute GVHD according to the MAGIC criteria. Death without previous acute GVHD will be a competing event.	Day 100
Secondary	Cumulative incidence of non-relapse/progression related mortality	Time to onset of disease relapse or progression (imaging, morphologic or molecular). Non-relapse related mortality will be a competing event.	Day 365
Secondary	Cumulative incidence of Chronic GVHD	Time to onset of 2014 NIH Chronic GVHD. Non-relapse related mortality will be a competing event.	Day 365
Secondary	Change in 36-Item Short Form Health Survey (SF-36)	Change in mean subscale response of the SF-36 Survey version 2.0 (Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Energy/fatigue, Emotional well-being, Social	Baseline, Days 30, 90, 180, and 365
Secondary	Change in the Functional Assessment of Cancer Therapy (FACT)-Bone Marrow Transplantation (BMT) Survey	Change in mean subscale response of the FACT-BMT survey	Baseline, Days 30, 90, 180, and 365
Secondary	Frequency of Grade 3-5 adverse events	Adverse events will be classified according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 5.0	Day 30
Secondary	Change in Natural Killer cell function [% activity]		Days 30, 90, and 180
Secondary	Change in lymphocyte subsets [absolute number/mcL]		Days 30, 90, and 180
Secondary	Cumulative incidence of CMV and EBV reactivation		Day 100
Secondary	Change in bone marrow or peripheral blood donor chimerism [%]		Days 30, 90, and 180
Secondary	Change in mean free mycophenolic acid and mycophenolic acid glucuronide level [mcg/mL] on peripheral blood (controls only)		Days 12 and 19